Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction

Kenneth C. Chu, Moon S. Chen, Mark B. Dignan, Emmanuel Taylor, Edward Partridge, Terrance Albrecht, Claudia Baquet, Laura Beebe, Dedra Buchwald, Clayton Chong, Kathryn Coe, Graham Colditz, Mark Dignan, Paula A. Espinoza, Paul A. Godley, Margaret K. Hargreaves, James R. Hebert, Ronda Henry-Tillman, Elmer Huerta, Judith S KaurHoward Koh, Grace X. Ma, Cathy D. Meade, Amelie Ramirez, David Satcher, Sora Park Tanjasiri, Beti Thompson, Victor Williams Tofaeono

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND. There are analogies between the development of therapeutic drugs for cancer and the development of interventions for reducing cancer health disparities. In both cases, it can take between 12 and 15 years for the benefits to become apparent. METHODS. The initial preclinical phase of drug development is analogous to the development of community partnerships and helping the community learn about cancer. The preclinical phase of in vitro and in vivo testing is analogous to identifying the disparities in the community. Then clinical testing begins with phase 1, toxicity, and dose-establishing studies. Analogously, community-based participatory research is used to develop disparities-reducing interventions (DRIs) within the community. RESULTS. The phase 2 clinical studies to determine whether the drug has activity are analogous to the DRI being implemented in the community to determine whether it can cause behavioral changes that will reduce cancer health disparities. If a drug passes phase 1 and 2 studies, phase 3 clinical trials are initiated. These are controlled studies to examine the efficacy of the drug. The similar activity for disparities research is to determine whether the DRI is better than the current standard/usual practice in controlled trials. If the drug is beneficial, the final phase is the dissemination and adoption of the drug. Analogously in disparities, if the DRI is beneficial, it is disseminated and is culturally adapted to other racial/ethnic groups and finally adopted as standard practice. CONCLUSIONS. The process of creating an effective DRI can be envisioned to have 4 stages, which can be used to aid in measuring the progress being made in reducing cancer health disparities.

Original languageEnglish (US)
Pages (from-to)2790-2796
Number of pages7
JournalCancer
Volume113
Issue number10
DOIs
StatePublished - Nov 15 2008
Externally publishedYes

Fingerprint

Health
Pharmaceutical Preparations
Neoplasms
Therapeutics
Community-Based Participatory Research
Phase III Clinical Trials
Ethnic Groups
Research

Keywords

  • Cancer health disparity
  • Community-based participatory research
  • Disparities-reducing intervention
  • Information dissemination
  • Therapeutic drugs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chu, K. C., Chen, M. S., Dignan, M. B., Taylor, E., Partridge, E., Albrecht, T., ... Tofaeono, V. W. (2008). Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction. Cancer, 113(10), 2790-2796. https://doi.org/10.1002/cncr.23879

Parallels between the development of therapeutic drugs and cancer health disparity programs : Implications for disparities reduction. / Chu, Kenneth C.; Chen, Moon S.; Dignan, Mark B.; Taylor, Emmanuel; Partridge, Edward; Albrecht, Terrance; Baquet, Claudia; Beebe, Laura; Buchwald, Dedra; Chong, Clayton; Coe, Kathryn; Colditz, Graham; Dignan, Mark; Espinoza, Paula A.; Godley, Paul A.; Hargreaves, Margaret K.; Hebert, James R.; Henry-Tillman, Ronda; Huerta, Elmer; Kaur, Judith S; Koh, Howard; Ma, Grace X.; Meade, Cathy D.; Ramirez, Amelie; Satcher, David; Tanjasiri, Sora Park; Thompson, Beti; Tofaeono, Victor Williams.

In: Cancer, Vol. 113, No. 10, 15.11.2008, p. 2790-2796.

Research output: Contribution to journalArticle

Chu, KC, Chen, MS, Dignan, MB, Taylor, E, Partridge, E, Albrecht, T, Baquet, C, Beebe, L, Buchwald, D, Chong, C, Coe, K, Colditz, G, Dignan, M, Espinoza, PA, Godley, PA, Hargreaves, MK, Hebert, JR, Henry-Tillman, R, Huerta, E, Kaur, JS, Koh, H, Ma, GX, Meade, CD, Ramirez, A, Satcher, D, Tanjasiri, SP, Thompson, B & Tofaeono, VW 2008, 'Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction', Cancer, vol. 113, no. 10, pp. 2790-2796. https://doi.org/10.1002/cncr.23879
Chu, Kenneth C. ; Chen, Moon S. ; Dignan, Mark B. ; Taylor, Emmanuel ; Partridge, Edward ; Albrecht, Terrance ; Baquet, Claudia ; Beebe, Laura ; Buchwald, Dedra ; Chong, Clayton ; Coe, Kathryn ; Colditz, Graham ; Dignan, Mark ; Espinoza, Paula A. ; Godley, Paul A. ; Hargreaves, Margaret K. ; Hebert, James R. ; Henry-Tillman, Ronda ; Huerta, Elmer ; Kaur, Judith S ; Koh, Howard ; Ma, Grace X. ; Meade, Cathy D. ; Ramirez, Amelie ; Satcher, David ; Tanjasiri, Sora Park ; Thompson, Beti ; Tofaeono, Victor Williams. / Parallels between the development of therapeutic drugs and cancer health disparity programs : Implications for disparities reduction. In: Cancer. 2008 ; Vol. 113, No. 10. pp. 2790-2796.
@article{0a5291a442854161a09ff7e8c46da690,
title = "Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction",
abstract = "BACKGROUND. There are analogies between the development of therapeutic drugs for cancer and the development of interventions for reducing cancer health disparities. In both cases, it can take between 12 and 15 years for the benefits to become apparent. METHODS. The initial preclinical phase of drug development is analogous to the development of community partnerships and helping the community learn about cancer. The preclinical phase of in vitro and in vivo testing is analogous to identifying the disparities in the community. Then clinical testing begins with phase 1, toxicity, and dose-establishing studies. Analogously, community-based participatory research is used to develop disparities-reducing interventions (DRIs) within the community. RESULTS. The phase 2 clinical studies to determine whether the drug has activity are analogous to the DRI being implemented in the community to determine whether it can cause behavioral changes that will reduce cancer health disparities. If a drug passes phase 1 and 2 studies, phase 3 clinical trials are initiated. These are controlled studies to examine the efficacy of the drug. The similar activity for disparities research is to determine whether the DRI is better than the current standard/usual practice in controlled trials. If the drug is beneficial, the final phase is the dissemination and adoption of the drug. Analogously in disparities, if the DRI is beneficial, it is disseminated and is culturally adapted to other racial/ethnic groups and finally adopted as standard practice. CONCLUSIONS. The process of creating an effective DRI can be envisioned to have 4 stages, which can be used to aid in measuring the progress being made in reducing cancer health disparities.",
keywords = "Cancer health disparity, Community-based participatory research, Disparities-reducing intervention, Information dissemination, Therapeutic drugs",
author = "Chu, {Kenneth C.} and Chen, {Moon S.} and Dignan, {Mark B.} and Emmanuel Taylor and Edward Partridge and Terrance Albrecht and Claudia Baquet and Laura Beebe and Dedra Buchwald and Clayton Chong and Kathryn Coe and Graham Colditz and Mark Dignan and Espinoza, {Paula A.} and Godley, {Paul A.} and Hargreaves, {Margaret K.} and Hebert, {James R.} and Ronda Henry-Tillman and Elmer Huerta and Kaur, {Judith S} and Howard Koh and Ma, {Grace X.} and Meade, {Cathy D.} and Amelie Ramirez and David Satcher and Tanjasiri, {Sora Park} and Beti Thompson and Tofaeono, {Victor Williams}",
year = "2008",
month = "11",
day = "15",
doi = "10.1002/cncr.23879",
language = "English (US)",
volume = "113",
pages = "2790--2796",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Parallels between the development of therapeutic drugs and cancer health disparity programs

T2 - Implications for disparities reduction

AU - Chu, Kenneth C.

AU - Chen, Moon S.

AU - Dignan, Mark B.

AU - Taylor, Emmanuel

AU - Partridge, Edward

AU - Albrecht, Terrance

AU - Baquet, Claudia

AU - Beebe, Laura

AU - Buchwald, Dedra

AU - Chong, Clayton

AU - Coe, Kathryn

AU - Colditz, Graham

AU - Dignan, Mark

AU - Espinoza, Paula A.

AU - Godley, Paul A.

AU - Hargreaves, Margaret K.

AU - Hebert, James R.

AU - Henry-Tillman, Ronda

AU - Huerta, Elmer

AU - Kaur, Judith S

AU - Koh, Howard

AU - Ma, Grace X.

AU - Meade, Cathy D.

AU - Ramirez, Amelie

AU - Satcher, David

AU - Tanjasiri, Sora Park

AU - Thompson, Beti

AU - Tofaeono, Victor Williams

PY - 2008/11/15

Y1 - 2008/11/15

N2 - BACKGROUND. There are analogies between the development of therapeutic drugs for cancer and the development of interventions for reducing cancer health disparities. In both cases, it can take between 12 and 15 years for the benefits to become apparent. METHODS. The initial preclinical phase of drug development is analogous to the development of community partnerships and helping the community learn about cancer. The preclinical phase of in vitro and in vivo testing is analogous to identifying the disparities in the community. Then clinical testing begins with phase 1, toxicity, and dose-establishing studies. Analogously, community-based participatory research is used to develop disparities-reducing interventions (DRIs) within the community. RESULTS. The phase 2 clinical studies to determine whether the drug has activity are analogous to the DRI being implemented in the community to determine whether it can cause behavioral changes that will reduce cancer health disparities. If a drug passes phase 1 and 2 studies, phase 3 clinical trials are initiated. These are controlled studies to examine the efficacy of the drug. The similar activity for disparities research is to determine whether the DRI is better than the current standard/usual practice in controlled trials. If the drug is beneficial, the final phase is the dissemination and adoption of the drug. Analogously in disparities, if the DRI is beneficial, it is disseminated and is culturally adapted to other racial/ethnic groups and finally adopted as standard practice. CONCLUSIONS. The process of creating an effective DRI can be envisioned to have 4 stages, which can be used to aid in measuring the progress being made in reducing cancer health disparities.

AB - BACKGROUND. There are analogies between the development of therapeutic drugs for cancer and the development of interventions for reducing cancer health disparities. In both cases, it can take between 12 and 15 years for the benefits to become apparent. METHODS. The initial preclinical phase of drug development is analogous to the development of community partnerships and helping the community learn about cancer. The preclinical phase of in vitro and in vivo testing is analogous to identifying the disparities in the community. Then clinical testing begins with phase 1, toxicity, and dose-establishing studies. Analogously, community-based participatory research is used to develop disparities-reducing interventions (DRIs) within the community. RESULTS. The phase 2 clinical studies to determine whether the drug has activity are analogous to the DRI being implemented in the community to determine whether it can cause behavioral changes that will reduce cancer health disparities. If a drug passes phase 1 and 2 studies, phase 3 clinical trials are initiated. These are controlled studies to examine the efficacy of the drug. The similar activity for disparities research is to determine whether the DRI is better than the current standard/usual practice in controlled trials. If the drug is beneficial, the final phase is the dissemination and adoption of the drug. Analogously in disparities, if the DRI is beneficial, it is disseminated and is culturally adapted to other racial/ethnic groups and finally adopted as standard practice. CONCLUSIONS. The process of creating an effective DRI can be envisioned to have 4 stages, which can be used to aid in measuring the progress being made in reducing cancer health disparities.

KW - Cancer health disparity

KW - Community-based participatory research

KW - Disparities-reducing intervention

KW - Information dissemination

KW - Therapeutic drugs

UR - http://www.scopus.com/inward/record.url?scp=55849098905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55849098905&partnerID=8YFLogxK

U2 - 10.1002/cncr.23879

DO - 10.1002/cncr.23879

M3 - Article

C2 - 18780311

AN - SCOPUS:55849098905

VL - 113

SP - 2790

EP - 2796

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -